- Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies
-
Motoya S, Watanabe M, Kim HJ, Kim YH, Han DS, Yuasa H, Tabira J, Isogawa N, Arai S, Kawaguchi , Hibi T
- KMID: 2417664
- Intest Res.
- 2018 Jul;16(3):499-501.
- doi: 10.5217/ir.2018.16.3.499
The authors regret an error in the reporting of Inflammatory Bowel Disease Questionnaire (IBDQ) patient-reported outcome data in the manuscript. A data extraction error resulted in incorrect IBDQ data being... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
-
Hisamatsu T, Kim HJ, Motoya S, Suzuki Y, Ohnishi Y, Fujii N, Matsushima N, Zheng R, Marano CW
- KMID: 2521602
- Intest Res.
- 2021 Oct;19(4):386-397.
- doi: 10.5217/ir.2020.00080
Background/Aims: We aimed to evaluate the efficacy and safety of ustekinumab (UST) in the East-Asian population with moderate to severely active ulcerative colitis (UC). Methods: This sub-analysis was conducted on data... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
-
Hibi T, Motoya S, Hisamatsu T, Hirai F, Watanabe K, Matsuoka K, Saruta M, Kobayashi T, Feagan BG, Tasset C, Besuyen R, Yun C, Crans G, Zhang J, Kondo A, Watanabe M
- KMID: 2539010
- Intest Res.
- 2023 Jan;21(1):110-125.
- doi: 10.5217/ir.2021.00143
Background/Aims: The safety and efficacy of filgotinib, a once-daily oral Janus kinase 1 preferential inhibitor, were evaluated in Japanese patients with ulcerative colitis (UC) in the phase 2b/3 SELECTION trial. Methods:... -
- CITED
-
- Close
- SHARE
-
- Close
- Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies
-
Motoya S, Watanabe M, Kim HJ, Kim YH, Han DS, Yuasa H, Tabira J, Isogawa N, Arai S, Kawaguchi , Hibi T
- KMID: 2417675
- Intest Res.
- 2018 Apr;16(2):233-245.
- doi: 10.5217/ir.2018.16.2.233
BACKGROUND/AIMS: Tofacitinib is an oral, small-molecule Janus kinase inhibitor being investigated for ulcerative colitis (UC). In OCTAVE Induction 1 and 2, patients with moderately to severely active UC received placebo... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study
-
Hibi T, Motoya S, Ashida T, Sai S, Sameshima , Nakamura S, Maemoto A, Nii M, Sullivan B, Gasser Jr , Suzuki Y
- KMID: 2454746
- Intest Res.
- 2019 Jul;17(3):375-386.
- doi: 10.5217/ir.2018.00141
BACKGROUND/AIMS: Inhibition of α4β7 integrin has been shown to be effective for induction and maintenance therapy in patients with ulcerative colitis (UC). We investigated the effects of varying doses of... -
- CITED
-
- Close
- SHARE
-
- Close
- Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from Japan
-
Komoto S, Motoya S, Nishiwaki , Matsui T, Kunisaki R, Matsuoka K, Yoshimura , Kagaya T, Naganuma M, Hida N, Watanabe M, Hibi T, Suzuki Y, Miura S, Hokari R, Japanese study group for pregnant women with IBD
- KMID: 2425286
- Intest Res.
- 2016 Apr;14(2):139-145.
- doi: 10.5217/ir.2016.14.2.139
BACKGROUND/AIMS: Anti-tumor necrosis factor drugs (anti-TNF) and thiopurines are important treatment options in patients with inflammatory bowel disease (IBD), including during pregnancy. However, there are limited data on the benefit/risk... -
- CITED
-
- Close
- SHARE
-
- Close
- Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries
-
Kobayashi , Hisamatsu , Suzuki Y, Ogata H, Andoh A, Araki T, Hokari R, Iijima H, Ikeuchi H, Ishiguro Y, Kato S, Kunisaki R, Matsumoto , Motoya S, Nagahori M, Nakamura S, Nakase H, Tsujikawa , Sasaki M, Yokoyama K, Yoshimura , Watanabe K, Katafuchi , Watanabe M, Hibi T
- KMID: 2417669
- Intest Res.
- 2018 Apr;16(2):168-177.
- doi: 10.5217/ir.2018.16.2.168
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease of the gastrointestinal tract, with increasing prevalence worldwide. IBD Ahead is an international... -
- CITED
-
- Close
- SHARE
-
- Close
